ABAL.L Regulatory News (ABAL)

28 Feb 2008 10:01

Imaginatik PLC28 February 2008 Imaginatik plc ("Imaginatik" or the "Company") Pfizer Strategic Investment - Update 28 February 2008 The Company announced on 21 February 2008 that Pfizer Inc. ("Pfizer") had agreedto subscribe for up to 12,953,368 new ordinary shares ("Subscription Shares"). The subscription price for a Subscription Share ("Subscription Price") andnumber of Subscription Shares to be issued is based upon a 5% premium to theaverage closing offer price of an ordinary share in Imaginatik over the fivedealing days following that announcement, being 21 February to 27 February 2008.This Subscription Price has now been calculated as 6.22209 pence perSubscription Share and Pfizer has subscribed for a total of 8,035,885Subscription Shares representing 6.45 per cent. of the enlarged share capital. Completion is conditional on admission to trading on AIM of the SubscriptionShares occurring on or by 13 March 2008 ("Admission"). Application forAdmission has been made today and is expected to occur on 6 March 2008. Each Subscription Share will be issued credited as fully paid and free from allliens, equities, charges, encumbrances and other interests and will upon theirissue rank in full for all dividends and distributions thereafter declared, madeor paid after Admission and shall otherwise rank pari passu in all respectswith, and carry the same voting and dividend rights as, the existing ordinaryshares. Pfizer has also agreed not to dispose of its interest in the SubscriptionShares for a period of twelve months following Admission and for a subsequentperiod of twelve months not to dispose of such interests other than throughW.H. Ireland Limited or the Company's broker at the time, without in each casethe consent of the Company, and save in each case in certain limitedcircumstances. Following the Subscription, the Company will have 124,637,111 ordinary shares inissue. The above figure may be used by shareholders as the denominator for thecalculations by which they will determine if they are required to notify theirinterest in, or a change to their interest in, the Company. For further information please contact: Imaginatik plc Tel: +44 (0)20 7917 2975Mark Turrell, CEO / Shawn Taylor, CFO W.H. Ireland Tel: +44 (0)121 265 6330Tim Cofman/Katy Birkin Investor relations and UK media Tel: +44 (0)20 7651 8688ICISTom Moriarty / Caroline Evans Jones US media relations Tel: +1 202-652-2250Adam Dubitsky About Imaginatik Imaginatik is the leading provider of innovation and collaborative problemsolving software and process to the world's leading companies. More than 100clients rely on Imaginatik's software, consulting and research to enable theirbest-of-breed innovation activities. Named as a World Economic Forum Technology Pioneer for 2008 and a finalist forthe IBM Lotus Awards 2008 in the Best Industry Solution category, Imaginatik'ssoftware and consulting services have helped clients discover significantsources of additional revenue, as well as tangible cost savings, processimprovements and increased product pipeline. Imaginatik is also committed todeveloping strategic solutions in the field of innovation, working with academicinstitutions such as the London Business School and the Cass School of Business,London, as well as leading practitioners of corporate innovation. For further information please visit http://www.imaginatik.com This information is provided by RNS The company news service from the London Stock Exchange